ArticleEuropean journal of nuclear medicine and molecular imaging2022
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical PET Imaging Evaluation of 68Ga-NB381 Probe in Multiple Myeloma
Clinical PET Imaging Evaluation of 68Ga-BC1 Probe in Multiple Myeloma
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Multifunctional CD38 in the pathogenesis and treatment of B-cell lymphomas.American journal of blood research · 2026Review
- Rapid and specific immunoPET imaging of Nectin-4 in gastric cancer and non-small cell lung cancer using [European journal of nuclear medicine and molecular imaging · 2025Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Advances in immunoPET/SPECT imaging: The role of Fab and F(ab')Acta pharmaceutica Sinica. B · 2025Review
- CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies.European journal of nuclear medicine and molecular imaging · 2025Article
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- Theranostic role ofEuropean journal of nuclear medicine and molecular imaging · 2024Article
- CD38-Specific Gallium-68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Application of the Nicoya OpenSPR to Studies of Biomolecular Binding: A Review of the Literature from 2016 to 2022.Sensors (Basel, Switzerland) · 2023Review
- Bovine lactoferrin inhibits SARS-CoV-2 and SARS-CoV-1 by targeting the RdRp complex and alleviates viral infection in the hamster model.Journal of medical virology · 2023Article
- State-of-the-art of nuclear medicine and molecular imaging in China: after the first 66 years (1956-2022).European journal of nuclear medicine and molecular imaging · 2022Article
- CD38-specific nanobodies allowFrontiers in immunology · 2022Article
- Noninvasive Evaluation of EGFR Expression of Digestive Tumors UsingMolecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
purposeAbnormal CD38 expression in some hematologic malignancies, including lymphoma, has made it a biomarker for targeted therapies. Daratumumab (Dara) is the first FDA-approved CD38-specific monoclonal antibody, enabling successfully immunoPET imaging over the past years. Radiolabeled Dara however has a long blood circulation and delayed tumor uptake which can limit its applications. The focus of this study is to develop
methodsF(ab')
resultsFlow cytometry and SPR assay proved the specific binding ability of Dara-F(ab')
conclusions[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.